News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Feb 16, 2017

  Insmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017
• Feb 14, 2017

  Insmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent
• Jan 4, 2017

  Insmed to Present at the 35th Annual J.P. Morgan Healthcare Conference
• Nov 14, 2016

  Insmed to Participate at November Investor Conferences
• Nov 3, 2016

  Insmed Reports Third Quarter 2016 Financial Results and Provides Business Update

  Enrollment objective achieved in phase 3 CONVERT study
• Oct 27, 2016

  Insmed to Host Third Quarter 2016 Financial Results Conference Call on Thursday, November 3, 2016
• Oct 18, 2016

  Insmed Announces Publication of Phase 2 Study of ARIKAYCE in Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

  Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE's potential to achieve early and sustained negative sputum cultures
• Oct 5, 2016

  Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
• Sep 27, 2016

  Insmed Appoints Roger Adsett as Chief Commercial Officer
• Sep 8, 2016

  Insmed to Participate at September Investor Conferences

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download